Table 1.

Clinical and laboratory characteristics of HIV-exposed and infected children with drug resistant tuberculosis

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
DR	MDR	MDR	MDR	MDR	INH monoresistant
Study arm	Placebo	Placebo	INH	INH	Placebo
HIV status	Negative	Negative	Negative	Positive	Negative
Age at TB diagnosis (months)	15.1	16.4	22.7	6.5	17.6
Gender	Male	Female	Male	Female	Female
TB contact*	Household contact, smear positive, DST unknown	None documented	None documented	Household contact, bacteriology unknown	Household contact, smear positive, DST unknown
Type TB	Pulmonary	Pulmonary	Pulmonary	Pulmonary	Pulmonary
Chest radiographic findings	Hilar adenopathy and alveolar consolidation	Alveolar consolidation	Hilar adenopathy	Hilar and paratracheal adenopathy and alveolar consolidation,	Hilar adenopathy and alveolar consolidation
Regimen received	RIF, INH, PZA, ETO × 6 months	RIF, INH, PZA, ETO × 6 months	RIF, INH, PZA, ETO × 2 months	RIF, INH, PZA, ETO × 2 months; ART started at age 3 months	RIF, INH, PZA, EMB, OFL × 9 months
Outcome at 6 months	Well, remained well at 2 years post-treatment	Well, remained well at 2 years post-treatment*	Lost to follow-up 2 months following initiation of TB therapy**	Died 2 months after TB diagnosis during a hospital admission to initiate MDR therapy	Well at 6 months, lost to follow-up following completion of therapy

^*These contacts were only reported at/after TB diagnosis

^**Phenotypic MDR diagnosis never available at or during treatment

DR: drug resistance, MDR: multidrug resistance, RIF: rifampicin, INH: isoniazid, PZA: pyrazinamide, ETO: ethionamide; OFX (ofloxacin)

Regimens presented are the final treatment regimen, as recorded by site.